Tariff Powerplay

The latest salvo of trade measures from Washington reveals a strategy that is less about correcting trade deficits and more about reshaping the geography of global production. By announcing a 100 per cent import duty on branded and patented drugs, alongside steep levies on heavy trucks and household furnishings, the United States is making a calculated bid to pull capital and capacity back to its own soil.

Companies that already manufacture in America, or pledge to build factories there, are spared the harshest penalties. Everyone else must choose between investing in the US or surrendering a critical market. This is not a mere skirmish over prices. Pharmaceutical products are among the most research-intensive and globally interlinked goods in the world. Their supply chains depend on a delicate balance of intellectual property rights, regulatory approvals and specialised manufacturing.

Advertisement

Even if generic medicines are exempt, the move sets a precedent that governments can use tariffs as a lever to direct high-value investment. The aim is clear: ensure that the next breakthrough cancer drug or advanced biologic is produced within American borders, where jobs and profits remain under domestic political control. This shift also signals a future where supply chains are judged not only by cost or efficiency but by political loyalty, forcing firms to weigh market access against production independence. For India, the immediate trade impact may appear limited.

Patented drugs form only a small slice of our pharmaceutical exports to the United States, which are dominated by generics. Yet the shockwaves are already visible. Indian markets tumbled as investors anticipated higher costs for contract manufacturing and feared a wider crackdown on healthcare products. The blow landed just as Indian technology companies were digesting a $100,000 fee on H-1B visas, another policy that raises the cost of operating in America. Two of India’s most export-oriented sectors ~ IT services and pharmaceuticals ~ now face simultaneous headwinds. The real danger lies beyond today’s tariffs.

If the world’s largest consumer economy can impose such sweeping conditions on life-saving medicines, it can do so on other advanced industries. Each targeted duty creates pressure for firms to relocate research, production and even talent to the US, where policy makers can claim job creation as a political victory. Countries like India, which aspire to move up the value chain in pharmaceuticals, biotechnology and digital services, risk being caught in a slow erosion of competitiveness if they cannot match these investment incentives. India’s response must therefore be more strategic than reactive.

Strengthening our own manufacturing ecosystem, streamlining regulatory approvals and negotiating trade arrangements that protect critical sectors will matter more than short-term market interventions. The message from Washington is unmistakable: economic nationalism is no longer confined to slogans. It is being enforced through tariffs that seek not only to protect today’s industries but to command the industries of tomorrow.